Comment on: Khalaf DJ, Sunderland K, Eigl BJ, et al. Health-related Quality of Life for Abiraterone Plus Prednisone Versus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer: Results from a Phase II Randomized Trial. Eur Urol 2018.
Abiraterone plus prednisone or enzalutamide in patients with metastatic castration-resistant prostate cancer: is a question of quality? / Lavacchi, Daniele; Mini, Enrico; Roviello, Giandomenico. - In: AME MEDICAL JOURNAL.. - ISSN 2520-0518. - ELETTRONICO. - 4:(2019), pp. 24-26. [10.21037/amj.2019.04.01]
Abiraterone plus prednisone or enzalutamide in patients with metastatic castration-resistant prostate cancer: is a question of quality?
Lavacchi, Daniele;Mini, Enrico;Roviello, Giandomenico
2019
Abstract
Comment on: Khalaf DJ, Sunderland K, Eigl BJ, et al. Health-related Quality of Life for Abiraterone Plus Prednisone Versus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer: Results from a Phase II Randomized Trial. Eur Urol 2018.
File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
amj-04-24.pdf
accesso aperto
Tipologia:
Pdf editoriale (Version of record)
Licenza:
Creative commons
Dimensione
131.88 kB
Formato
Adobe PDF
|
131.88 kB | Adobe PDF |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
